
Walmart vs. The TJX Companies: Which Retailer Has the Edge in 2025?
As consumers prioritize value in today's cost-conscious retail environment, two retail leaders — Walmart Inc. WMT and The TJX Companies, Inc. TJX — have emerged as top contenders for investor attention. WMT leverages its massive scale and low-price strategy to dominate everyday essentials, while TJX excels in the off-price retail segment, offering well-known brands at significant discounts through stores like T.J. Maxx and Marshalls. The key question for investors is: which stock delivers stronger value right now?
Both companies are performing well in a cautious consumer environment, but they operate with very different playbooks. Walmart is investing heavily in technology, logistics, and high-margin initiatives like advertising and memberships to drive growth. The TJX Companies, meanwhile, thrives on agility and treasure-hunt shopping experiences, supported by a global footprint and lean operations.
Let's break down how WMT and TJX stack up across key areas like business fundamentals, growth outlook, valuation and earnings potential — and what it means for investors in 2025.
The Case for WMT
Walmart is delivering steady growth in 2025, driven by its massive retail footprint and ongoing investments in digital innovation. Its successful omnichannel strategy — combining physical stores with a fast-growing e-commerce platform — is helping the company attract consistent traffic across channels. With diversified revenue streams that include brick-and-mortar sales, online shopping, advertising, and memberships, Walmart has built a resilient and scalable business model that is well-positioned for long-term success.
Walmart is gaining momentum from high-margin growth drivers like Walmart Connect, its retail media advertising platform, and Walmart+, its paid membership program. In the first quarter of fiscal 2026, advertising revenues surged 50%, while membership income rose 14.8%. These results highlight Walmart's effective shift toward tech-driven, higher-margin services that boost both profitability and customer retention.
A key driver of Walmart's ongoing success is its advanced omnichannel strategy. The company continues to invest heavily in data analytics, digital infrastructure, and in-store enhancements to create a seamless shopping experience across both physical and online platforms. In the fiscal first quarter, global e-commerce sales grew 22%, fueled by strong demand for store-fulfilled pickup and delivery options. Backing this growth is Walmart's enhanced last-mile delivery network, which is on track to offer same-day delivery to 95% of U.S. households — a major advantage in today's speed-focused retail landscape.
Walmart has entered 2025 on strong footing, but management has cautioned about potential headwinds ahead, particularly from tariffs and broader economic uncertainty. In addition, currency fluctuations may impact performance across international markets. Still, WMT's expanding e-commerce presence, compelling value proposition and rising contributions from high-margin areas offer a solid buffer against short-term volatility and help support long-term growth.
The Case for TJX
The TJX Companies has consistently proven its ability to execute in challenging environments. The company's strength lies in its flexible sourcing, quick inventory turns and international diversification. It is not just about offering low prices — it is about offering premium brands at a discount, a model that continues to resonate with shoppers seeking value and variety.
The company's off-price retail model continues to resonate with a broad customer base, as seen in the steady rise in customer transactions and comparable store sales. In the first quarter of fiscal 2026, TJX's comparable store sales rose 3%, led by higher customer traffic across both apparel and home categories. Growth was consistent across all divisions, including Marmaxx and HomeGoods in the United States, as well as TJX Canada and TJX International, reinforcing the company's strong value proposition.
The TJX Companies continues to build on this momentum through global expansion and digital growth initiatives. It ended the quarter with 5,121 stores, adding 36 new locations during the period. The company is also enhancing its e-commerce presence to capture additional market share as more consumers shop online. Internationally, TJX is growing its TK Maxx banner in Europe and Australia and plans to enter Spain in fiscal 2027. Strategic investments in Grupo Axo in Mexico and Brands For Less in the Middle East are opening new growth avenues in promising global markets.
A key advantage for TJX is its flexible supply chain and healthy inventory position, with total inventory up 15% year over year. This ensures a steady flow of fresh merchandise and supports its treasure-hunt shopping appeal. While near-term challenges like higher payroll costs, tariff pressures, and currency fluctuations may weigh on margins, The TJX Companies is taking proactive steps to mitigate these risks.
How Does the Zacks Consensus Estimate Compare for WMT & TJX?
The Zacks Consensus Estimate for Walmart's fiscal 2026 earnings per share (EPS) has been steady at $2.59 over the last 30 days, suggesting year-over-year growth of 3.2%. In contrast, the EPS estimate for The TJX Companies' fiscal 2026 has moved down by a penny to $4.46, indicating year-over-year growth of 4.7%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Price Performance & Valuation of WMT & TJX
Over the past 12 months, Walmart stock has delivered an impressive 39.8% return, significantly outpacing the broader S&P 500 Index, which rose 9.5% during the same period. Meanwhile, The TJX Companies has recorded 11% growth in its stock price.
One-Year Price Performance
From a valuation standpoint, Walmart currently trades at a forward price-to-earnings (P/E) ratio of 35.10x. Meanwhile, The TJX Companies trades at a more modest forward P/E of 26.42x.
Bottom Line
Both Walmart and The TJX Companies are well-positioned to benefit from today's value-driven retail environment. While TJX continues to perform well with its off-price model, global store expansion, and solid customer traffic, Walmart's broader revenue streams — including advertising, memberships, and e-commerce — provide stronger earnings visibility and higher-margin growth. With a more consistent EPS outlook, superior stock performance and ongoing investments in digital transformation, Walmart emerges as the more attractive retail stock heading into the second half of 2025.
TJX and Walmart currently carry a Zacks Rank #3 (Hold) each. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
The TJX Companies, Inc. (TJX): Free Stock Analysis Report
Walmart Inc. (WMT): Free Stock Analysis Report
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
36 minutes ago
- CBC
Canada won't delay digital services tax during U.S. trade negotiations, says finance minister
Canada won't put a hold on the digital services tax on big tech companies set to take effect on June 30, the finance minister said Thursday. Pressure has mounted on Ottawa to hold off while the government is in trade discussions with the U.S., which opposes the tax. Finance Minister François-Philippe Champagne said the legislation was passed by Parliament, and Canada is "going ahead" with the tax. "The [digital services tax] is in force and it's going to be applied," he told reporters before a cabinet meeting on Parliament Hill. The digital services tax will hit companies like Amazon, Google, Meta, Uber and Airbnb with a three per cent levy on revenue from Canadian users. It will apply retroactively, leaving U.S. companies with a $2-billion US bill due at the end of the month. A June 11 letter signed by 21 members of Congress said U.S. companies would pay 90 per cent of the revenue Canada collects from the tax. Canadian and U.S. business groups, organizations representing U.S. tech giants and American lawmakers have all signed letters in recent weeks calling for the tax to be eliminated or paused. It is set to take effect just weeks before a deadline Canada and the U.S. have set for coming up with a new trade deal. The Canadian Chamber of Commerce and other organizations have warned retaliatory measures in a U.S. budget bill could hit Canadians' pension funds and investments. Champagne said Canada isn't the only country that could be affected by those retaliatory measures. "These are discussions at the global level," he said in French. Champagne said there's a wider discussion going on among G7 nations about tax regimes. David Pierce, the Canadian Chamber of Commerce's vice-president of government relations, said in an earlier interview his organization fears Canada could "aggravate an already very tricky trade discussion" if it goes ahead with the tax and the retroactive payment requirement. The Liberals first promised the tax in the 2019 election, but it was delayed for years due to global efforts to establish a broader, multinational digital taxation plan.


Globe and Mail
38 minutes ago
- Globe and Mail
Anti‑Obesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP‑1 Incretins and Uptake of Oral Treatments
Mordor Intelligence has published a new report on the Anti‑Obesity Drugs Market, offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction Mordor Intelligence, in its latest anti‑obesity drugs market report, forecasts the market to reach from USD 25.93 billion in 2025 to USD 100.97 billion by 2030, advancing at a 31.24 % CAGR. The anti-obesity drugs market focuses on medications developed to aid in weight loss and manage obesity related conditions. Obesity is a chronic, relapsing condition associated with several health issues, including type 2 diabetes, cardiovascular diseases, sleep apnea, and certain cancers. As global obesity rates rise driven by sedentary lifestyles, poor dietary habits, and genetic factors, there is growing demand for medical interventions beyond lifestyle changes and bariatric surgery. Key Trends The anti‑obesity drugs landscape is being reshaped by several important developments: 1. GLP‑1 receptor agonists gaining dominance Gut‑hormone incretins, primarily GLP‑1 agonists, are set to expand at 33.15 % CAGR through 2030. Their strong efficacy in reducing weight and favorable safety profiles have led major pharmaceutical companies to scale up production and secure lifecycle extensions for these agents 2. Oral formulations on the rise Although injectables account for 81.3 % of the 2024 market share, oral anti‑obesity drugs are projected to grow at an impressive 36.6 % CAGR through 2030. This surge reflects patient preference for pill-based therapies and investment in oral GLP‑1 pills by developers. 3. Prescription segment maintains leadership Prescription drugs commanded 84.2 % of the anti‑obesity drugs market in 2024. Over‑the‑counter options trail behind but are gaining traction, with the prescription category still growing at a 32.56 % CAGR through 2030 4. Digital pharmacies unlocking access Retail pharmacies held 54.05 % of the market in 2024, but online pharmacies are catching up. They are expected to grow at a 34.75 % CAGR, spurred by e‑commerce ease and expanding reimbursement support. 5. Asia‑Pacific emerging fast North America remains the largest market with a 65.9 % revenue share in 2024. However, Asia‑Pacific is advancing at a robust 33.65 % CAGR, driven by rising healthcare spending and expanding obesity awareness. Market Segmentation The anti‑obesity drugs market can be segmented in multiple ways, enabling stakeholders to identify growth pockets and tailor strategies. By Mechanism of Action Peripherally acting drugs led revenue in 2024, capturing 60.10% of the market. These medications act within the digestive system, such as fat‑absorption inhibitors and appetite suppressants, reducing energy uptake or signalling fullness. Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through 2030. These therapies mimic or enhance gut hormones to regulate appetite and blood sugar. Prescription drugs held a dominant share at 84.20% in 2024. This category includes clinically validated medications with regulatory backing and reimbursement frameworks. Over‑the‑counter (OTC) drugs occupy a smaller share but are gradually gaining influence through ease of access and increasing consumer trust. By Route of Administration Injectables commanded 81.30% of the market in 2024, driven by the widespread use of injectable GLP‑1 therapies known for their strong efficacy. Oral drugs are emerging as the most dynamic segment, projected to grow at a 36.60% CAGR from 2025 to 2030, reflecting a clear patient trend toward pills over injections. By Distribution Channel Retail pharmacies made up 54.05% of market revenues in 2024, remaining the standard way for patients to obtain anti‑obesity medications. Online pharmacies are fast growing (projected 34.75% CAGR to 2030), propelled by telehealth, convenient home delivery, and evolving reimbursement policies. By Geography North America was the largest regional market, securing a 65.90% share in 2024. This dominance stems from advanced healthcare systems, approval frameworks, and strong payer support. Asia‑Pacific is the fastest expanding region, with a projected CAGR of 33.65%. Growth drivers include rising obesity awareness, healthcare investments, and broader pharmaceutical access. Key Players Roche Roche is a global pharmaceutical company that has recently entered the anti-obesity drugs market. The company has secured licensing agreements for potential weight loss candidates, signaling its interest in expanding its portfolio to include obesity treatments. Roche's expertise in biotechnology and commitment to addressing unmet medical needs position it as a noteworthy participant in the obesity care landscape. GlaxoSmithKline (GSK) GSK is a multinational healthcare company involved in the development of various therapeutic areas, including obesity. The company is exploring the potential of amylin analogs and other hormonal agents for weight management. GSK's research initiatives aim to provide patients with alternative treatment options and contribute to the advancement of obesity care. Novo Nordisk Novo Nordisk is a leading global healthcare company specializing in diabetes and obesity care. The company has developed several GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), which have shown significant efficacy in weight management. Novo Nordisk continues to invest in research and development to expand its portfolio of anti-obesity medications and enhance patient outcomes. Currax Pharmaceuticals Currax Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for obesity. Through strategic acquisitions, such as obtaining rights to Contrave, Currax has expanded its presence in the anti-obesity drugs market. The company's focus on addressing obesity-related health issues aligns with the growing demand for effective weight management therapies. Eli Lilly and Company Eli Lilly is another major player in the anti-obesity drugs market, known for its innovative therapies. The company's GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), has demonstrated promising results in clinical trials for weight loss. Eli Lilly's commitment to obesity care is reflected in its ongoing research efforts and strategic partnerships aimed at advancing treatment options for patients. Conclusion The anti‑obesity drugs market is entering a transformative era, with expected growth from USD 25.93 billion in 2025 to USD 100.97 billion by 2030 at a 31.24 % CAGR. This growth is fuelled by the powerful clinical outcomes of GLP‑1 agonists, innovation in oral formulations, expanded access via online pharmacies, and increasing attention to obesity as a chronic disease. While North America remains the dominant market, Asia‑Pacific's rapidly growing demand offers substantial opportunities. Competition is intensifying, as established pharmaceutical companies and biotechs alike race to advance next generation therapies and diversify distribution channels. As market dynamics evolve, stakeholders should monitor: • Progress of oral GLP‑1 candidates and dual/triple‑agonists like CagriSema • Regulatory approvals and reimbursement pathways, especially in emerging regions • Competitive responses from lifecycle extensions to partnerships and acquisitions • Supply chain robustness and accessibility, particularly amid supply constraints for high‑demand drugs In sum, the anti‑obesity drugs market is poised for significant expansion, with transformative treatments and shifting delivery models likely to reshape global healthcare delivery and patient outcomes. Industry Related Reports Ozempic Market : The Ozempic Market Report is segmented by region, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report provides both value (in USD) and volume (in units) for each of these segments. Japan Oral Anti-Diabetic Drug Market: The Japan Oral Anti-Diabetic Drug Market Report is segmented by drug types, including Biguanides, Alpha-Glucosidase Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, and others, as well as end users, such as Hospitals/Clinics, Personal/Home Care Settings, and others. The report provides market size and forecasts for each segment in terms of value (USD). Get More Insights: Anti-Snoring Market: The Anti-Snoring Devices Market report segments the industry by device type, including Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) Devices, and other device types. It also segments by surgical procedures such as Uvulopalatopharyngoplasty (UPPP), Somnoplasty, Pillar Procedure, Tonsillectomy, Radiofrequency Palatoplasty, and more. Additionally, the report covers geographical segmentation. About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@


CBC
41 minutes ago
- CBC
Ottawa unveils new countermeasures for Canada's steel, aluminum sectors amid U.S. trade war
Prime Minister Mark Carney laid out a slew of new trade war countermeasures focused on the steel and aluminum industries in Canada on Thursday, including a commitment to adjust counter-tariffs on July 21 depending on how trade talks with Washington progress.